Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Stockholders??? Equity

v3.24.1.1.u2
Condensed Consolidated Statements of Stockholders’ Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Series A Preferred Stock
Preferred Stock
Series B Preferred Stock
Preferred Stock
Series C Preferred Stock
Preferred Stock
Series D Preferred Stock
Preferred Stock
Series E Preferred Stock
Preferred Stock
Series F Preferred Stock
Preferred Stock
Series F-1 Preferred Stock
Preferred Stock
Series F-2 Preferred Stock
Preferred Stock
Common Stock
Common Stock
Beginning balance (in shares) at Dec. 31, 2022         251 1,443 500,756 1,058 0       338,033
Beginning balance at Dec. 31, 2022 $ 530   $ 88,533 $ (88,005) $ 0 $ 0 $ 0 $ 0 $ 0       $ 2
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Exercise of common stock warrants (in shares)                         109,257
Exercise of common stock warrants 2,062   2,061                   $ 1
Issuance of common stock in connection with conversion of notes (in shares)                         31,466
Issuance of common stock in connection with conversion of notes 516   516                    
Commitment to issue shares of common stock in connection with March waiver agreement 298   298                    
Deemed dividend for repricing of Series D preferred stock     6 (6)                  
Issuance of common stock/at-the-market offering, net of offering costs (in Shares)                         211,667
Issuance of common stock/at-the-market offering, net of offering costs 2,107   2,106                   $ 1
Issuance of Series E preferred stock in connection with LOC (in shares)                 5,000        
Issuance of Series E preferred stock in connection with LOC 4,350   4,350                    
Stock-based compensation (in shares)                         38,335
Stock-based compensation 181   181                    
Net loss (2,300)     (2,300)                  
Ending balance (in shares) at Mar. 31, 2023         251 1,443 500,756 1,058 5,000       728,758
Ending balance at Mar. 31, 2023 7,744   98,051 (90,311) $ 0 $ 0 $ 0 $ 0 $ 0       $ 4
Beginning balance (in shares) at Dec. 31, 2023         251 1,443 500,756 0 0 4,448 653 1,153 25,744,158
Beginning balance at Dec. 31, 2023 4,677   121,665 (116,995) $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 7
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Issuance of common stock in connection with equity line of credit (in shares)                         21,133,689
Issuance of common stock in connection with equity line of credit 1,391 $ 3 1,388                    
Issuance of common stock/at-the-market offering, net of offering costs (in Shares)                         4,824,382
Issuance of common stock/at-the-market offering, net of offering costs 588   588                    
Stock-based compensation 274   274                    
Net loss (4,612)     (4,612)                  
Ending balance (in shares) at Mar. 31, 2024         251 1,443 500,756 0 0 4,448 653 1,153 51,702,229
Ending balance at Mar. 31, 2024 $ 2,318   $ 123,915 $ (121,607) $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 10